-
STCube begins dosing in P2 trial of nelmastobart for lung cancer
22 Jan 2026 07:03 GMT
… or metastatic non-small cell lung cancer (NSCLC).
The phase 2 study … 75 mg/m² of docetaxel. The study is currently underway … have long relied on docetaxel-based chemotherapy. Current docetaxel monotherapy in Korea …
-
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
13 Jan 2026 12:15 GMT
… datopotamab deruxtecan) compared to docetaxel in patients with TROP2 NMR … nonsquamous non-small cell lung cancer (NSCLC) without actionable … diagnostic for DATROWAY in lung cancer. The device was … About Non-Small Cell Lung Cancer
Lung cancer is the most common …
-
<![CDATA[Phase 1/2 Data Support Systemic Olvi-Vec in Lung Cancer]]>
07 Jan 2026 18:43 GMT
… with relapsed or refractory lung cancers,” said Thomas Zindrick, … path trials in progressive lung cancers, addressing a significant … second half and additional lung cancer trial readouts anticipated … checkpoint inhibitor compared to docetaxel in NSCL cancer ( …
-
Combined Use of Radioactive 125I Seeds and PD-1 Inhibitor Provides Sustained Clinical Benefit in an Elderly Patient with Advanced Non-Small Cell Lung Cancer: A Case Report
07 Jan 2026 13:23 GMT
… elderly patients with advanced lung cancer who are unsuitable … of chemotherapy consisting of docetaxel (120 mg) and … NSCLC, non-small cell lung cancer; PFS, prolonged progression-free … for a lung cancer: a narrative review. Transl Lung Cancer Res. 2021 …
-
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
05 Jan 2026 13:00 GMT
… cell lung cancer (SCLC) and progressive non-small cell lung cancer … with relapsed or refractory lung cancers,” said Thomas Zindrick … trials in progressive lung cancers, addressing a significant … checkpoint inhibitor compared to docetaxel in NSCLC. Additionally …
-
AZ's ATR inhibitor ceralasertib flunks lung cancer test
22 Dec 2025 17:11 GMT
… -L1 inhibitor Imfinzi (durvalumab) or docetaxel, a standard second-line treatment … immune response of patients with lung cancer whose tumours stopped responding to … improve outcomes for patients with lung cancer through our industry-leading portfolio …
-
<![CDATA[OncoPrism-NSCLC Test Predicts Key Clinical Outcomes in Lung Cancer]]>
19 Dec 2025 18:59 GMT
… the OncoPrism-non–small cell lung cancer (NSCLC) test, a clinical … OS in patients treated with docetaxel (n = 193), nor … predicts which [patients with] lung cancer will benefit from immunotherapy—leaving … trial who were treated with docetaxel (n = 193); the …
-
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
06 Dec 2025 20:30 GMT
… squamous non-small cell lung cancer (sqNSCLC). Gotistobart … America Conference on Lung Cancer, hosted by the … who received chemotherapy (docetaxel) as second or … lung cancer (“NSCLC”) covers all epithelial lung cancers other than small cell lung cancer …
-
<![CDATA[One-time TIL therapy shows durable responses in advanced lung cancer]]>
19 Nov 2025 23:34 GMT
… nonsquamous non-small cell lung cancer (NSCLC), according to … has progressed despite chemoimmunotherapy.
Lung cancer remains the leading cause … release. Standard-of-care docetaxel in a similar patients … head and neck, and lung cancers.
The new NSCLC findings …
-
The Efficacy and Safety of Anlotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Achieved Stable Disease (SD) After Two Cycles of First-Line Chemotherapy Combined with Immunotherapy: A Retrospective Cohort Study
14 Nov 2025 21:29 GMT
… A. Evolving trends in lung cancer: epidemiology, diagnosis, … docetaxel or pemetrexed shows promising activities against non-small cell lung cancer … non-small cell lung cancer. Lung Cancer. 2018;122:32 … non-small cell lung cancer (NSCLC). Lung Cancer. 2024;187: …
About
© 1995-2026